Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Development by Quarter
Development — Outsourced services ex-drug supply (FY2013–FY2018, $M) ($M)
Vertex Pharmaceuticals Development: $84.8M in Q4 2018, down 1.6% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2018 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
Reported in Form 10-Q / 10-K MD&A (Development Expenses Disaggregation Table).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development — Outsourced services ex-drug supply (FY2013–FY2018, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2018 | Dec 31, 2018 | 84.8 | -1.6% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| Q3 2018 | Sep 30, 2018 | 81.3 | -9.3% | Form 10-Q (a2018q310-q.htm, filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 93.5 | +5.2% | Form 10-Q (a2018q210-q.htm, filed 2018-07-26) ↗ |
| Q1 2018 | Mar 31, 2018 | 84.7 | +15.7% | Form 10-Q (a2018q110-q.htm, filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 86.2 | – | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 89.6 | – | Form 10-Q (a2018q310-q.htm, filed 2018-10-25) ↗ |
| Q2 2017 | Jun 30, 2017 | 88.9 | – | Form 10-Q (a2018q210-q.htm, filed 2018-07-26) ↗ |
| Q1 2017 | Mar 31, 2017 | 73.2 | – | Form 10-Q (a2018q110-q.htm, filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Development ($M), quarterly Q1 2017–Q4 2018 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-outsourced-pure
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.